Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention

Novo Nordisk (NYSE: NVO) hasn't been getting much love on Wall Street. The stock trades down 66% from its 2024 highs and just took a big hit after the company offered weak guidance for 2026. However, for contrarian dividend investors, Novo Nordisk could be an undervalued opportunity. First, Novo Nordisk's bad news Novo Nordisk was the first company to introduce a GLP-1 weight loss shot. Unfortunately, it couldn't keep up with demand, which allowed compounded versions of the company's Wegovy to be sold. An ...